600 MADISON AVENUE, SUITE 1601, NEW YORK, NY
Investor Presentation
Annual Report to Security Holders
Reports Fiscal Year 2026 Financial Results and Provides Corporate Update
Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer
iBio, Inc. Schedules 2026 Annual Meeting for October 14, 2026
Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study
Reports Q3 Fiscal Year 2026 Financial Results and Provides Corporate Update
Appoints Distinguished Biotech Leader, Elizabeth Stoner, to its Board of Directors
FY 2025
Q3
Q2
Amended Quarterly Report
Q1
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities Offered under a Shelf Registration
Notice of Exempt Offering of Securities
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Amended Schedule 13G - Ownership Report
Initial Statement of Beneficial Ownership
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report
Correspondence
Submission Upload